JAZZ Stock Recent News

Target Action (PDUFA) Date set for November 29, 2024 If approved, zanidatamab will be the first HER2-targeted treatment specifically indicated for patients with HER2+ locally advanced or metastatic biliary tract cancer DUBLIN, May 29, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review of the Biologics License Application (BLA) for zanidatamab, the human epidermal growth factor receptor 2 (HER2)-targeted bispecific antibody, for the treatment of previously treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer (BTC). Under the Prescription Drug User Fee Act (PDUFA), FDA has set a target action date of November 29, 2024.

Now that the federal government is finally taking action on cannabis rescheduling — moving it to Schedule III and creating de facto medical cannabis legalization — many are wondering about the status of cannabis stocks as a whole. Cannabis stocks, as a whole, spiked upwards on the news but quickly reverted to pre-announcement norms.

DUBLIN , May 22, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced a strategic collaboration with Life Science Cares to drive social impact through employee volunteerism in the United States. This partnership reinforces Jazz's commitment to supporting the communities in which employees work and live.

If the market's dramatic shifts this year leave you discombobulated, you're not alone. But, despite widespread overvaluation across a range of tech stocks, plenty of cheap blue-chip stocks are ready to offer the portfolio stability we're all desperately seeking.

Among the emerging industries that have captured the attention of investors is the cannabis sector. The cannabis industry has experienced remarkable growth, giving rise to a new breed of top cannabis stocks to buy for investments in May.

Review Jazz's (JAZZ) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.

Jazz's (JAZZ) first-quarter earnings and sales miss the mark. The company reaffirms its guidance for full-year 2024.

The headline numbers for Jazz (JAZZ) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Jazz (JAZZ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Jazz Pharmaceuticals is rated as a "Buy" due to its current financial health, multiple near-term catalysts, and projected growth for 2024 and 2025. The company's successful commercial products include Xywav, Epidiolex, and Rylaze, which have shown increasing adoption and sales revenues. JAZZ is targeting low-hanging fruit in oncology with its drug Zanidatamab, which has the potential to become a blockbuster drug with up to $2 billion/year in net sales.